Preveceutical Stock Price, News & Analysis

PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has announced a change in its auditing firm. The company's board of directors has accepted the resignation of Smythe LLP as their former auditor and appointed Davidson & Company LLP as the successor auditor, effective December 18, 2024. The new auditor will serve until the company's next annual general meeting of shareholders.

The company confirms there were no reservations in the former auditor's reports during their tenure, and no reportable events exist between PreveCeutical and Smythe LLP. The required documentation, including the Notice of Change of Auditor and letters from both auditing firms, has been reviewed by the audit committee and board of directors and will be filed on SEDAR.

PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Patroski J. Lawson as an independent director effective December 6, 2024. According to CEO Stephen Van Deventer, Lawson brings extensive experience in government affairs across local, state, federal, and global levels, particularly within the healthcare sector. The company expects his strategic insights and leadership to strengthen their governance and advocacy efforts as they navigate the regulatory landscape in developing innovative therapies.

PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Barry Ticho to its Scientific Advisory Board effective December 1, 2024. Dr. Ticho brings over 25 years of biopharma and drug development expertise, currently serving as Chief Medical Officer at Stoke Therapeutics. His experience includes co-founding Verve Therapeutics and leading R&D initiatives at Moderna Therapeutics, Pfizer, and Biogen.

Dr. Ticho has notably transformed Stoke from a 9-employee private company to a publicly traded organization with over 100 employees, focusing on genetic diseases in neurology and ophthalmology. He holds an MD and PhD from the University of Chicago and serves on multiple Scientific Advisory Boards including Cardior Pharmaceuticals, Mana.bio, and Sania.

PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board effective December 1, 2024. Dr. Gallagher brings over 25 years of experience in biotech and pharmaceutical investments, having served as Managing Partner at Trekk Venture Partners and Partner at Abingworth. His notable achievements include overseeing Sirtris Pharmaceuticals' $720 million acquisition by GlaxoSmithKline and contributing to Translate Bio's $3.2 billion acquisition by Sanofi.

Dr. Gallagher holds a Ph.D. in Organic Chemistry from the University of Michigan and has served as Chairman of eFFECTOR Therapeutics. His expertise spans venture capital, strategic investments, and corporate development within the biotech sector.

PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Stephen Glover as an independent director effective November 30, 2024. The company's CEO, Stephen Van Deventer, highlighted Glover's expertise in biopharma, corporate strategy, commercialization, and financial management, noting his track record in building and transforming organizations aligns with BioGene's mission to advance groundbreaking therapies.

PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Deepak Sampath as an independent director effective November 21, 2024. Dr. Sampath brings over 25 years of experience in molecular biology, pharmacology, and drug development. Currently serving as Senior Vice President and Head of Research at Ultragenyx, he has contributed significantly to oncological treatments, including the FDA approval of venetoclax for CLL/SLL. His expertise spans protein biologics, nucleic acids, and gene therapies, with 108 published articles and involvement in 32 patents/applications. At Ultragenyx, he leads research in genetic conditions across neurological, metabolic, bone, and muscular diseases.

PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Professor Mirela Delibegovic, FRSE to its Scientific Advisory Board effective November 19, 2024. The company, which focuses on developing preventive and curative therapies using organic and nature-identical products, expects to benefit from Delibegovic's expertise in obesity and diabetes physiology and signaling research to advance their therapeutic programs in metabolic health.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced two key appointments at its subsidiary BioGene Therapeutics Inc. Dr. Linnea Olofsson joins as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer, effective November 16, 2024. Dr. Parekh brings over two decades of experience in pharmaceutical chemistry and drug/gene delivery systems from The University of Queensland's School of Pharmacy. Dr. Olofsson contributes expertise in biophysics, oncology, molecular biology, and CRISPR/Cas9 gene editing. These appointments aim to advance BioGene's scientific initiatives and therapeutic applications development.

PreveCeutical Medical has completed the intellectual property asset sale transaction with its subsidiary BioGene Therapeutics. The transaction, valued at USD$1,353,227, involves PreveCeutical and PreveCeutical Australia selling certain intellectual property assets to BioGene. The payment structure includes USD$500,000 in cash to be paid within 24 months and 16,000,000 common shares of BioGene at USD$0.0533 per share. PreveCeutical plans to distribute a portion of these shares to its shareholders at a future date.